spacer
home > ebr > Summer 2014
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2014

   
Text
PDF
Editor’s Letter

Deborah O'Neil contemplates the industry's changing climate and reflects on some of this edition's focus features.
 
view
download pdf
bullet
STRATEGY AND FINANCE
Dry Shipping

The Physics of Failure


Dan O’Donnell at Fisher BioServices urges companies to pay closer attention to the basic principles of physics when distributing cell-based products. This will allow the focus to stay on the patients and clinical trials, and not on delivery.
 
view
download pdf
bullet
BioResearch and Innovation
gmMSC Technology

Mesenchymal Stem Cells 2.0


Technological breakthroughs in the development of next generation mesenchymal stem cells are leading to increasing patient benefits, as well as clinical and commercial success, thinks apceth’s Stefanos Theoharis.
 
view
download pdf
Oral Diseases

Mouth to Mouth


Pierre Attali at BioAlliance Pharma considers why systemic and topical treatments for oral diseases are not always the best option, and recommends the use of mucoadhesive buccal formulations as an alternative.
 
view
download pdf
Iminosugars
 
A Rare Approach


The successful development of iminosugar-based chaperone compounds could be the answer to treating lysosomal storage diseases and many other orphan pathologies. Julie Charollais-Thoenig and Stéphane Demotz at Dorphan SA explain.
 
view
download pdf
Placenta-Derived Therapeutics

Great Expectations


With preeclampsia still a leading killer of pregnant women and a major contributor to foetal morbidity, Pluristem Therapeutics’ Karine Kleinhaus talks about the need to invest research into placenta-derived cell therapies.
 
view
download pdf
Genetic Toxicology

Genotox Support


Andrew Eaton and Matthew Tate at Gentronix muse on how an understanding of genetic toxicology can help chemists to formulate and improve compounds in an effective way.


 
view
download pdf
bullet
Discovery Technology
Column Technology

HPLC’s Golden Jubilee


In the first of a two-part series, Ronald Majors from Agilent Technologies looks back at the origins of high-performance liquid chromatography, and reflects on how far this technology has come on the eve of its 50th anniversary.
 
view
download pdf
Novel Therapeutics

Lease of Life


Novozymes Biopharma’s Dermot Pearson suggests how extending the therapeutic half-life of drugs can offer pharma companies new prospects to improve the
profile of their products.
 
view
download pdf
Hypoxia Replication

Prime Conditions


Investigators are embracing new hypoxia workstations which push the boundaries of research capabilities by enabling the capture of real-time dissolved oxygen directly from cell-culture media. Michael Rau at Oxford Optronix reports.
 
view
download pdf
bullet
BioDevelopment and Regulatory
Regulatory Update

New Twists for Orphans


Fresh changes at the FDA have had important implications for the orphan drug development process. Timothy Coté at Coté Orphan Consulting guides companies and sponsors through the regulatory minefield.
 
view
download pdf
Cell-BasedPotency Assays

Quality Assurance

When developing a cell-based potency assay intended for product release and quality control, careful considerations need to be taken. Weihong Wang at Eurofins Lancaster Laboratories investigates.


 
view
download pdf
Biosimilars

Making Progress


There has been increasing recognition of the value of biosimilars as a cost-effective answer to the problem of patent expiry and demands for lower priced alternatives. NDA Group’s Dr Gopalan Narayanan provides some thoughts.


 
view
download pdf
Patent Protection

The Secret of Success


Bioproduction processes can offer companies the chance to exploit new subject matter to extend the patent life of a drug. This rise in second-generation copyrights is prompting legal moves, says Paul Calvo at Sterne, Kessler, Goldstein and Fox.
 
view
download pdf
bullet
BIOINFORMATICS
Whole Genome Sequencing

Applied Information


Rodrigo Barnes at Aridhia Informatics believes that annotation services are the solution to delivering research data concerning genome sequencing to both clinicians and patients.
 
view
download pdf
bullet
INTERVIEW
Industry Interview

Radiation Response

Xstrahl’s Adrian Treverton talks to EBR about the future direction of radiation oncology, and how it can provide more patient-centred healthcare.
 
view
download pdf
bullet
INDUSTRY DYNAMICS
Clinical Research Outsourcing

Merging Markets


Vijaya Vulapalli at GBI Research explores how clinical research outsourcing partners are set to cash in on the opportunities presented by pharma’s tough times.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

New Temperature Profiles from a Global Study

Laminar Medica

Recently there has been an influx of temperature mapping studies to collect sufficient ambient data to develop temperature profiles.  Solid temperature profiles on specific shipping routes are required to ensure streamlined packaging and robust lane qualification. The most reliable method to develop temperature profiles is to capture the actual reading from shipments, as well as using the historical and meteorological data to increase the confidence level.
More info >>

Industry Events

10th Annual NGS & Clinical Diagnostics Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 10thAnnual NGS & Clinical Diagnostics Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement